Black Diamond Therapeutics announces positive Phase 2 silevertinib results

BDTX•2026-11-10

Black Diamond Therapeutics said updated Phase 2 results showed an 86% CNS-ORR in patients with untreated brain metastases. The company said FDA feedback supports pivotal development and potential accelerated approval based on CNS-ORR.

Black Diamond Therapeutics announces positive Phase 2 silevertinib results

1. Updated trial results

Related News

Janus Henderson Investors UK raises Elmos Semiconductor voting rights to 3.02% from 2.94%

Gain Therapeutics Q3 net loss narrows 40% to $3.16 million

Olema Pharma Q3 net loss widens on higher costs

Kailera to present Phase 3 ribupatide trial designs at ObesityWeek 2026

Affiliated Managers Group target price raised by Deutsche Bank to $458 from $426